Drug Trial Radar · NCT02255656
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
Last checked: Nov 20, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,062
Actual
Start
Jan 7, 2015
Primary completion
Jul 15, 2020
Study completion Jul 15, 2020
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 2, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To evaluate long-term safety of alemtuzumab. Secondary Objectives: * To evaluate long term efficacy of alemtuzumab. * To evaluate the safety profile of participants who received other Disease Modifying Treatment (DMT) following alemtuzumab treatment. * To evaluate participant-reported Quality of Life (QoL) outcomes and health resource utilization of participant who received alemtuzumab. * To evaluate as needed re-treatment with alemtuzumab and other DMTs.
Conditions
- Relapsing Remitting Multiple Sclerosis
Interventions
alemtuzumab GZ402673Drug
Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)Time frame: From Baseline until the end of the study (up to a maximum duration of 5.6 years)
- Number of Participants With Infusion-Associated Reactions (IAR)Time frame: Within 24 hours of any alemtuzumab infusion
- Number of Participants With Adverse Events of Special Interest (AESI)Time frame: From Baseline until the end of the study (up to a maximum duration of 5.6 years)
- Number of Participants With Potentially Clinically Significant Laboratory AbnormalitiesTime frame: From Baseline until the end of the study (up to a maximum duration of 5.6 years)
Locations
131 sites in 19 countries. Site status is shown where the registry gives one.
Investigational Site Number 1086
Cullman, Alabama
Investigational Site Number 1031
Phoenix, Arizona
Investigational Site Number 1171
Phoenix, Arizona
Investigational Site Number 1090
Tucson, Arizona
Investigational Site Number 1040
Berkeley, California
Investigational Site Number 1152
Fullerton, California
Investigational Site Number 1093
Pasadena, California
Investigational Site Number 1027
Fort Collins, Colorado
Investigational Site Number 1078
Jacksonville, Florida
Investigational Site Number 1059
Maitland, Florida
Investigational Site Number 1173
Sarasota, Florida
Investigational Site Number 1034
Sunrise, Florida
Investigational Site Number 1005
Tampa, Florida
Investigational Site Number 1049
Tampa, Florida
Investigational Site Number 1008
Northbrook, Illinois
Investigational Site Number 1001
Fort Wayne, Indiana
Investigational Site Number 1024
Indianapolis, Indiana
Investigational Site Number 1017
Des Moines, Iowa
Investigational Site Number 1022
Kansas City, Kansas
Investigational Site Number 1083
Lenexa, Kansas
Investigational Site Number 1039
Lexington, Kentucky
Investigational Site Number 1021
Louisville, Kentucky
Investigational Site Number 1061
Wellesley, Massachusetts
Investigational Site Number 1028
Worcester, Massachusetts
Investigational Site Number 1025
Ann Arbor, Michigan
Investigational Site Number 1020
Detroit, Michigan
Investigational Site Number 1054
Traverse City, Michigan
Investigational Site Number 1084
Kansas City, Missouri
Investigational Site Number 1092
St Louis, Missouri
Investigational Site Number 1073
Teaneck, New Jersey
Investigational Site Number 1014
Albuquerque, New Mexico
Investigational Site Number 1081
Mineola, New York
Investigational Site Number 1026
New York, New York
Investigational Site Number 1160
Patchogue, New York
Investigational Site Number 1015
Rochester, New York
Investigational Site Number 1053
Syracuse, New York
Investigational Site Number 1095
Chapel Hill, North Carolina
Investigational Site Number 1082
Winston-Salem, North Carolina
Investigational Site Number 1035
Cleveland, Ohio
Investigational Site Number 1058
Uniontown, Ohio
Showing 40 of 131 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.